1 Although no accurate data exist as to the blood flow of the normal human spleen, it can be roughly computed from knowledge of the hemoglobin content and blood mixing time. Since the normal spleen contains about 7 g of hemoglobin (10) , or approximately 1 per cent of that of circulating blood, and since, according to Harris, McAlister and Prankerd (11) , splenic "mixing" of normal Cr`1-labeled red cells occurs within about 15 seconds, the normal splenic blood flow may be estimated to be approximately 1 per cent per 0.25 minute, or 4 per cent per minute.
In the second manner of red cell removal, more severe alterations of red cells are involved and the cells are sequestered diffusely throughout the reticuloendothelial system. Thus the liver, with its great mass, is the chief site of trapping. Such hepatic trapping ensues when red cells have been exposed to agglutinating antibodies (1, 2), complement-fixing antibodies (12, 13) , agglutinating metallic cations (1, 3) , sodium arsenate (4), and sterile incubation at 370 C for 24 hours or more (5) . In general, these alterations involve either gross aggregation of red cells or a nearlytic injury to the cell membrane. When injected, small amounts of such cells are usually cleared rapidly, with half-disappearance rates of from 1.5 to 6 minutes. This presumably reflects the large blood flow of all the reticuloendothelial organs combined, among which the liver is foremost. In general, hepatic trapping of red cells kinetically resembles that of foreign particulate matter of many kinds. Although erythrophagocytosis may be provoked by some of the forms of red cell injury enumerated above, and although phagocytosis is often regarded as the essence of foreign particle clearance (14) , phagocytosis is not visible during the initial stage in the hepatic trapping of red cells (15) .
To what extent the contrasting pathways of red cell trapping outlined above are determined by qualitative, and to what extent by quantitative, factors is not certain. At least three purely quantitative factors are presumed to be involved: 1) the quantity of altered red cells present; 2) the extent of the alteration; 3) the quantity of filtering (largely reticuloendothelial) tissue available (2) . Although with respect to immune mechanisms, earlier studies had shown that the amount of antibody (anti-D) added to the appropriate (type D) red cells in vitro influenced the rate at which the 1145 affected cells were trapped by the spleen (2), it has not been ascertained whether quantitative differences in the extent of a given alteration might change the predominant pathway of red cell destruction from splenic to hepatic, or vice versa. At least two previous observations suggested, albeit inconclusively, that this might be the case. 1) Whereas on injection into a normal subject, type D red cells sensitized in vitro with anti-D were selectively trapped in the spleen, type D red cells injected into immunized subjects whose plasma contained very high concentrations of anti-D were trapped to a moderate extent in the liver as well (2) . 2) Although the liver is the major site of sequestration when type B (or A) red cells are injected into subjects with detectable complete antibodies against such cells, at least some subjects with agammaglobulinemia (i.e., extreme hypogammaglobulinemia) sequester ABOincompatible red cells in the spleen (2, 16) .
There were inherent difficulties in the previous studies (2) of the quantitative effects of antibodv added to red cells in vitro in terms of the subsequent fate of these cells in vitro; such studies involve a variable dissociation of antibody from the red cell after its injection into the circulation. the rate of this dissociation depending in part on the D antigen concentrations of the injected red cells and of the recipient's red cells. In order to explore quantitative factors influencing the effects of antibodies on red cells in vivo, the studies reported below were carried out in man and in rats.
METHODS
Techniques applicable to studies in man StubJects. All studies relating to the effects of anti-B xwere carried out in a 56-year old woman with acquired agammaglobulinemia and less than 20 mg per 100 ml of gamma globulin in her serum. Previous studies (2) were applied for dilution of whole blood and of plasma by the anticoagulant.
Body surface radioactivity over the heart, liver and spleen of each subject was measured periodically as previously described (17) . At the conclusion of each experiment a complete body scan was conducted seeking high concentrations of radioactivity in other areas. None such was found.
Method of study in vivo. In each experiment involving passive immunization the subject was first injected with the sample of Cr5`-labeled, noncompatible red cells. For a period of 4 to 6 days the survival of these red cells and the subject's body surface radioactivity were followed. Then an amount of antiserum against the labeled cells, calculated to provide a desired ratio of antibody/red cells in the subject's circulation, was injected. During the subsequent several hours, numerous determinations of blood and corporeal radioactivity were made as illustrated in Figure 1 . The acutely falling levels of red cell radioactivity after injection of antiserum were plotted on semilogarithmic paper, and the half-survival time was computed. The change in organ radioactivity was obtained by subtracting the relative radioactivity over each organ (17) just prior to antiserum injection from that measured after the cessation of the acute hemolytic process. The red cell trapping activity of the spleen relative to the liver (S/L) was then estimated by dividing the increment in splenic radioactivity by the increment in hepatic activity. An example of these calculations, as carried out in the experiment portrayed in where AS and AL = increments in splenic and hepatic radioactivity, respectively, Sb and Lb= ratio of radioactivity spleen/precordium and liver/precordium, respectively, just before the injection of antiserum. Sa and La = ratio of radioactivity spleen/precordium and liver/ precor(lium, respectively, after the cessation of the acute hemolytic process.
Techniques applicable to studies in rats Subjects. The studies were made on large (400 to 500 g) males from a Bartonella-free strain (Charles River C. D.) of Sprague-Dawley rat. Techniques involving donor red cells and antiserum. The rat red cells involved in each experiment were derived from fresh defibrinated blood obtained by cardiac puncture of normal animals of the same strain. Antiserum against rat red cells was obtained from a single adult male New Zealand rabbit which had received monthly intraperitoneal injections of saline-washed rat red cells for 8 months. Freshly (drawn, this serum when incubated at 370 C with equal volumes of 5 per cent red cells in normal rat serum caused hemolysis to a titer of 1/100, agglutination to a titer of 1/100, and induced agglutinability in the presence of PVP to a titer of 1/8,000 (Table II) . After heating for 2 hours at 560 C, the same antiserum in the presence of large volumes of fresh rat serum, caused hemolysis only when undiluted, agglutination to a titer of 1/100, and agglutinability in PVP to a titer of 1/8,000. All studies in vivo involved the use of aliquots taken from a single frozen specimen of this antiserum after it had been heated as described.
Techniques involving Cr51. Rat red cells were labeled by adding 20 to 30 ,uc of Cr51 as Na2Cr5"O4 per ml of defibrinated rat blood, and agitating gently for 30 minutes at room temperature. The blood was then centrifuged, the serum removed, and the red cells made up to 50 per cent by volume in isotonic saline preparatory to the addition of antiserum (see below).
Radioactivity in the circulating blood of rats was assessed on blood obtained from small terminal incisions in the rats' tails. Two 0.1 ml samples were pipetted directly from the tail wound into test tubes suitable for use in a well-type scintillation counter. The first 0.1 ml sample was added to a tube containing 1.0 ml of heparinized water and was used to measure whole blood radioactivity. The second 0.1 ml sample was added to heparinized saline. This suspension was then centrifuged and the supernatant decanted into a second tube for the counting of plasma radioactivity. Red cell radioactivity was determined as the difference between whole blood and plasma radioactivity.
The radioactivity of rat livers, spleens, lungs, kidneys, and femurs was also determined in a well-type scintillation counter as described elsewhere (7) .
Method of study in vivo. To the saline suspension of Cr5`-labeled rat red cells was added an equal volume of a predetermined dilution of antiserum. This mixture was incubated at 370 C with continuous gentle agitation for 1 hour, whereupon it was centrifuged, the plasma discarded, and the cells made up to a 50 per cent suspension in fresh rat serum for injection. Each rat was injected by tail vein with 0.5 ml of labeled, antibody-treated red cells, and thereafter serial blood specimens were withdrawn by tail puncture. At approximately 2.5 hours the animals were sacrificed, and the various organs were weighed and counted.
Peripheral blood radioactivity as a percentage of injected Cr51 was calculated from the product of the Cr51 concentration and the estimated blood volume divided by the total injected dose. The blood volume in animals of this strain and size was shown by previous studies with Cr`1-labeled normal red cells to be approximately 4.5 per cent of body weight. Organ radioactivity was calculated both as a percentage of injected Cr51 and as the concentration of Cr5l per wet weight.
Miscellaneous techniques
The presence of frank agglutination of red cells was determined by adding 0.1 ml of cell suspension to 10 ml of saline and examining microscopically a drop of the suspension. Increased red cell agglutinability was determined with PVP as described elsewhere (18) . The presence of cell-adherent protein was determined by the technique of Coombs, Mourant and Race (19) . Com- plemenit fixation was determined in the usual manner (20) , but employing the same rabbit serum-rat red cell system in the complement assay. Plasma hemoglobin levels were determined by the benzidine technique (21), using the same specimens employed for measuring plasma radioactivity. RESULTS Anti-B. Five studies were carried out in the patient with agammaglobulinemia, and the data are presented in Table I . The chronological sequence of these experiments, involving differing ratios of antiserum/red cells, was randomized. During the four to six days prior to the injection of anti-B serum, the Cr5l-labeled type B red cells injected into the patient were destroyed at a relatively slow, steady rate, with estimated half-survival times of from 9 to 15 days. At the time of injection of the anti-serum, from 6.9 to 11.7 ml of red cells remained, except in the experiment involving a large dose of antiserum in which a smaller volume of cells was deliberately employed. XVhen a very small amount of antiserum was employed so that the estimated antiserum-red cell ratio in vivo was only 0.01, there followed a rapid disappearance of 23 A sharp rise in splenic radioactivity and a simultaneous, somewhat smaller increase in hepatic activity were observed. The injection of 0.07 ml of antiserum per ml type B red cells eliminated 87 per cent of the Cr5l-labeled red cells from the circulation, at the rate of 13.9 per cent per minute. This was associated with a very low level of Cr51 in the plasma with no definite point of maximal activity. In this experiment both spleen and liver radioactivity increased sharply and to about the same extent. The administration of 0.5 ml of antiserum per ml of type B red cells eliminated 100 per cent of the red cell radioactivity from the patient's circulation, at the rate of 34.7 per cent per minute. In this experiment (Figure 1) there followed a rise in plasma hemoglobin and of Cr51, the latter reaching a maximal level of 8.6 per cent of the injected dose 30 minutes after the injection of the antiserum. The rise in hepatic radioactivity was about double that over the spleen. Within two minutes of the injection of a large volume of antiserum, 10 hour. In the first study the hepatic Cr5l uptake slightly exceeded that of the spleen (S/P = 0.90); in the other the S/P ratio was only 0.65. One of these studies was included in a previous report (2) . bit antiserum per ml rat red cells), the red cells were incompletely and relatively slowly destroyed and the spleen was the dominant sequestering organ. At higher antiserum concentrations, however, in linear proportion to the quantity of antibody employed, trapping by the liver predominated (upper portion of Figure 3 ). As portrayed in the lower part of Figure 3 , this preemption by the liver of red cell trapping at high antibody doses was due to the tendency of this relatively massive organ to approach (but not to Figure 4 illustrates the fact that the sequestering activity of the spleen relative to that of the liver declined in linear proportion to the amount of antibody employed.
In Table V the effects of the rabbit serum antibody employed upon rat red cells in zitro are compared with those observed in vivo. Analogous to the human studies, titrations were carried out in a normal fresh rat serum medium. It is apparent from Table V upper portion of the figure it is evident that the total sequestration of Cr"-labeled red cells ("all tissues") increased in proportion to the antiserum/red cell ratio. The total splenic uptake of Cr" reached a maximum at an antiserum/red cell ratio of 0.33, when its ability to trap red cells was over 20 times that of the liver, on a gram-for-gram basis (lower portion). With larger amounts of antibody, the spleen and liver approximated each other in trapping ability per gram tissue (lower portion), and therefore the total liver uptake predominated. this antibody failed to provoke any red cell sequestration in the lungs or femur. The very low levels of radioactivity in the lungs correlated with the levels of activity remaining in the peripheral blood. Only when there was some evidence of intravascular hemolysis, as indicated by plasma radioactivity, was there any appreciable kidney radioactivity.
DISCUSSION
In general these studies support previous observations (1, 2) The studies with anti-B, an agglutinating, complement-fixing, potentially lytic antibody, indicated that it, too, had a spectrum of activity in vivo, ranging in its effects, when given in nonlytic doses, from a predominantly splenic to a strongly hepatic pattern of sequestration. With this antibody, however, splenic sequestration was less active than with anti-D, occurred over a rather narrow range of antibody/antigen proportion, and was selective only at barely injurious antibody concentrations which were, indeed, undetectable by their effects in vitro. 5 With small to moderate amounts of such antibody, a tendency for hepatic trapping to occur is manifest and predominates over a wide range of antibody-antigen ratios, until actual intravascular hemolysis is encountered. As shown in Figure 2 this relationship can be extrapolated to include, at the extreme, data on the actively immunized subject whose plasma contained a relative infinity of nonhemolytic agglutinating anti-B antibody. The spectrum of action in vivo of the potentially lytic and agglutinating antibody (anti-B), may, through quantitative variation, overlap the spectrum of action of the in5Presumably the lowest anti-B level was provided by the patient with agammaglobulinemia herself, prior to the present studies, when, despite lack of detectable antibody in vitro, she sequestered type B cells slowly, over several days, in the spleen. That splenic sequestration of normal red cells on an immune basis may occur despite the absence of incompatibility in vitro has been previously reported (22) ancd confirmed (23, 24 Figure 3 and Table IV that the liver assumed the major role in red cell destruction by pre-emption rather than by simply receiving the overflow from a "saturated" spleen. Finally, with large, lytic volumes of antiserum actual intravascular hemolysis was evident and radioactivity, presumably radioactive hemoglobin, accumulated for the first time in the kidney. This spectrum of hemolytic activity of rabbit antibody in rats closely paralleled that of anti-B in man (compare Tables I and V) . Thus, in these studies in rats the same antibody, or mixture of antibodies, was capable of causing three distinct patterns of hemolysis: 1) a slow, incomplete trapping of red cells in the spleen; 2) a rapid, complete sequestration, chiefly in the liver; and 3) an intravascular lysis with deposition of hemoglobin throughout the reticuloendothelial system and with spillage into the kidneys. Although previous studies in dogs had indicated that red cells coarsely agglutinated by metallic cations may lodge in the lungs (2) , in the present studies the lungs were devoid of red cell trapping activity, regardless of the intensity of agglutination of the injected red cells; nor was there evidence of hemoglobin uptake by the lungs. Furthermore, pulmonary sequestration of red cells, apart from extravasations into the alveoli, as in essential pulmonary hemosiderosis (25) , has not been observed experimentally or clinically in man. Thus it appears that the reticuloendothelial tissue of the lungs seldom, if ever, participates in hemolytic mechanisms.
The mechanisms by which antibody-injured red cells are sequestered are still in doubt. There is reasonably good, but necessarily indirect, evidence that incomplete agglutinins destroy red cells by rendering them agglutinable in the presence of fibrinogen and other anisometric macromolecules in vivo (2, 18) , which in turn leads to their low pressure filtration (26) by the spleen. Although it has been postulated that frankly agglutinating antibodies, such as anti-B, cause hepatic trapping by causing large, firm agglutinates which are also filterable by the relatively large liver sinusoids (2), the extensive, comparative studies of human iso-antibodies by Cutbush and Mollison (12, 13, 27) indicate that those antibodies which bind complement, without producing frank agglutination in vitro, also cause a rapid (probably hepatic) pattern of red cell destruction. Thus, in the present studies, some hepatic sequestration was observed at antibody concentrations which caused little or no agglutination in vitro. However, hepatic uptake of red cells was not pronounced until agglutinating amounts of antibody were employed. It appears that the liver may partially participate in red cell trapping, in a "spleen-like" fashion, either in the splenectomized subject (2) or in the presence of a vast excess of incomplete agglutinin, but that a purely hepatic pattern of destruction usually commences with, or is coincident with, actual red cell agglutination demonstrable in vitro. Whether the prime mechanism of hepatic sequestration involves a simple physical filtration of lattice-forming red cell agglutinates (26), possibly involving "uncoated" red cells (28) , or a surface adherence to fixed macrophages, is yet to be determined.
SUMMARY
The influence of antibody/antigen proportions on the kinetics of red cell destruction were studied in man and in rats.
The effects of anti-B iso-antibody were studied by passively immunizing an agammaglobulinemic patient with various amounts of anti-B serum and observing the pattern of destruction of a given amount of type B red cells. A spectrum of effects was observed, ranging from a slow partial trapping by the spleen with small doses to a brisk hepatic trapping with large doses, while still larger doses caused intravascular hemolysis.
The effects of incomplete anti-D iso-antibody were studied by passively immunizing each of several D-negative subjects with various amounts of anti-D serum and observing their effect upon given amounts of type D red cells. Although small and moderate amounts of antibody caused a mainly splenic pattern of destruction, large amounts caused a moderate hepatic uptake and were similar in their effects to very small amounts of anti-B antibody.
Studies on rats employing a rabbit antibody against rat red cells indicated a spectrum of action similar to that of anti-B in man: a slow, incomplete sequestration by the spleen occurred when small amounts of antibody were employed; a rapid, largely hepatic sequestration occurred with larger amounts; and with still larger amounts, intravascular lysis was seen, with hemoglobin deposition in the liver, spleen and kidney. The lungs and bone marrow did not participate in the sequestration process at any dose of antibody.
Although the kinetics of red cell destruction in vivo by complete and by incomplete agglutinins ordinarily differ, the differences are modified by purely quantitative factors.
